Physician profile
Ailee Orihuela
NPI 1659153310
$1,739.44
in general payments reported to CMS, 2019-2025
29 companies · $772 in 2025
The $772 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $968 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $171.43 | 2024-2025 | |
| Daiichi Sankyo INC. | $114.67 | 2024-2025 | Enhertu |
| Abbvie INC. | $111.03 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $103.22 | 2024-2025 | Opdivo, Opdualag |
| Incyte Corporation | $100.17 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals Lp | $99.20 | 2024-2025 | Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $92.69 | 2024-2025 | Lynparza, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $89.44 | 2024 | Fruzaqla, Ninlaro |
| Janssen Biotech, INC. | $74.11 | 2024-2025 | Erleada, Rybrevant, Tecvayli |
| Lilly USA, LLC | $73.06 | 2024-2025 | Jaypirca, Verzenio |
| Celgene Corporation | $71.85 | 2024-2025 | Reblozyl |
| Array Biopharma INC | $71.10 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $57.59 | 2024-2025 | Monoferric, Cosela |
| Kite Pharma, INC. | $54.13 | 2025 | Yescarta |
| Genentech USA, INC. | $50.47 | 2024 | Tecentriq, Phesgo, Polivy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $48.55 | 2024 | Brukinsa |
| Glaxosmithkline, LLC. | $39.84 | 2025 | Ojjaara, Blenrep |
| Puma Biotechnology, INC. | $39.32 | 2024-2025 | |
| Sobi, INC | $36.74 | 2024 | |
| Adc Therapeutics America, INC. | $30.11 | 2025 | |
| Kyowa Kirin, INC. | $29.28 | 2024 | Poteligeo |
| Pharmaessentia USA Corporation | $29.02 | 2024 | Besremi |
| Springworks Therapeutics, INC. | $25.57 | 2025 | Ogsiveo |
| Beone Medicines USA, INC. | $25.48 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $22.67 | 2025 | |
| Emd Serono, INC. | $22.35 | 2024 | |
| Astellas Pharma US INC | $21.42 | 2025 | Xtandi |
| Alexion Pharmaceuticals, INC. | $17.89 | 2025 | Ultomiris |
| Sumitomo Pharma America, INC. | $17.04 | 2025 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ailee Orihuela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.